Where competition is heating up in pharma

Oncology has long been king in pharma, at least in terms of R&D and revenue dollars. But plenty of other therapeutic areas are hotbeds of competition.

Immunology remains an especially attractive field with drugs that can target multiple indications, widening patient reach. The therapeutic area has also given rise to a slew of blockbusters including Humira and Stelara, and accounted for over one-fifth of the bestselling 50 drugs last year.